The gmp cell therapy consumables market size has grown exponentially in recent years. It will grow from $22.73 billion in 2025 to $28.79 billion in 2026 at a compound annual growth rate (CAGR) of 26.7%. The growth in the historic period can be attributed to expansion of clinical cell therapy trials, growth of regenerative medicine research, increasing adoption of gmp manufacturing standards, rising investments in cell-based therapies, availability of advanced cell culture tools.
The gmp cell therapy consumables market size is expected to see exponential growth in the next few years. It will grow to $73.96 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. The growth in the forecast period can be attributed to increasing commercialization of cell therapies, rising demand for scalable gmp production, expansion of gene and immunotherapy pipelines, growing focus on process automation, increasing regulatory scrutiny of cell therapy manufacturing. Major trends in the forecast period include increasing demand for gmp-compliant cell therapy consumables, rising adoption of single-use bioprocessing products, growing use of automated cell processing systems, expansion of standardized cell culture solutions, enhanced focus on quality and regulatory compliance.
The rising prevalence of chronic diseases is expected to drive growth in the GMP cell therapy consumables market. Chronic diseases are illnesses that last three months or longer and can worsen over time. The increase in chronic conditions has spurred research and development of innovative cell therapies aimed at addressing these diseases. As cell therapy applications expand across various chronic conditions, the demand for GMP consumables grows to ensure quality and consistency in clinical trials. Strict regulatory requirements and patient demand for advanced therapies further support market growth. For example, in June 2025, the World Health Organization (WHO), a Switzerland-based organization, reported that 1.8 million avoidable deaths occur annually in the European Region due to chronic noncommunicable diseases. Additionally, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based national library of medicine, projected that the global population with chronic diseases will reach 142.66 million by 2050, up from 71.52 million in 2020. Consequently, the growing prevalence of chronic diseases is fueling demand for GMP cell therapy consumables.
Leading companies in the GMP cell therapy consumables market are focusing on the development of GMP-compliant CD34+ hematopoietic stem cells (HSCs) to enhance advanced therapies. These GMP-compliant CD34+ HSCs are a specific type of stem cell that expresses the CD34 marker on their surface and is produced following Good Manufacturing Practice (GMP) standards. For example, in April 2024, OrganaBio, a US-based pharmaceutical firm, introduced HematoPAC-HSC-CB-GMP, a readily available source of GMP-compliant CD34+ HSCs obtained from fresh human cord blood. Leveraging its extensive expertise in cell isolation and GMP manufacturing, OrganaBio is able to yield high quantities of highly viable CD34+ HSCs within 24 hours post-collection. This launch aims to support the advancement of next-generation therapies for blood cancers and genetic disorders.
In March 2023, Sartorius AG, a Germany-based provider of bioprocess solutions, single-use technologies, and laboratory instruments for the biopharmaceutical industry, acquired Polyplus for approximately €2.4 billion (around US$2.6 billion). Through this acquisition, Sartorius aims to strengthen its position as a leading supplier of critical upstream technologies for cell and gene therapies by integrating Polyplus’s transfection reagents and GMP-grade plasmid DNA into its existing portfolio of cell culture media and other essential bioprocess components. This integration enhances Sartorius’s capability to support viral vector manufacturing workflows for advanced therapies. Polyplus, based in France, provides innovative upstream technologies for cell and gene therapies, developing and producing transfection reagents, DNA/RNA delivery reagents, and GMP-grade plasmid DNA, which are key components in the production of viral vectors for cell and gene therapies and other advanced medicinal products.
Major companies operating in the gmp cell therapy consumables market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Sartorius AG, Corning Incorporated, Avantor Inc., Fresenius Kabi AG, Miltenyi Biotec, Bio-Techne Corp, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., BioLife Solutions Inc., PromoCell GmbH, PeproTech Inc., Sino Biological Inc., Wilson Wolf Corporation, Cellexus Ltd., MaxCyte Inc., BioLegend Inc., Repligen Corporation, Terumo Corporation.
North America was the largest region in the GMP cell therapy consumables market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gmp cell therapy consumables market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gmp cell therapy consumables market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the GMP cell therapy consumables market by increasing costs of imported reagents, culture media, bioprocessing plastics, enzymes, and sterile single-use components used in cell manufacturing workflows. Clinical and commercial manufacturing facilities in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces cost pressure on large-scale production expansion. These tariffs are increasing operational costs and affecting supply continuity. However, they are also encouraging local consumable manufacturing, regional supplier diversification, and strengthened domestic bioprocess supply chains.
The gmp cell therapy consumables market research report is one of a series of new reports that provides gmp cell therapy consumables market statistics, including gmp cell therapy consumables industry global market size, regional shares, competitors with a gmp cell therapy consumables market share, detailed gmp cell therapy consumables market segments, market trends and opportunities, and any further data you may need to thrive in the gmp cell therapy consumables industry. This gmp cell therapy consumables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
GMP cell therapy consumables encompass consumable products and items manufactured in accordance with good manufacturing practices (GMP) guidelines for cell-based therapies. These consumables and tools designed for cell culture assist researchers in cultivating new cells in culture media, catering to various applications such as gene therapy, vaccine production, tissue culture, toxicity testing, and drug development.
The primary categories of GMP cell therapy consumables include kits, reagents or molecular biology reagents, growth factors or cytokines and interleukins, and other essential components. A kit is a compilation of items, such as tools or equipment, intended for a specific activity or purpose. In the realm of GMP cell therapy consumables, kits are utilized for tasks such as the isolation, expansion, harvesting, and formulation of cell therapies. These therapies encompass NK cell therapy, stem cell therapy, T-cell therapy, and others, involving processes such as cell collection and characterization or sorting and separation, cell culture and expansion or preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution or handling, process monitoring and control or re-administration or quality assurance, among others. GMP cell therapy consumables find application in clinical, commercial, and research settings.
The GMP cell therapy consumables market consists of sales of cell culture media, media supplements, extracellular matrices, flasks, tubes, dishes or cryovials, serological pipettes, or centrifugation tubes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The gmp cell therapy consumables market size is expected to see exponential growth in the next few years. It will grow to $73.96 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. The growth in the forecast period can be attributed to increasing commercialization of cell therapies, rising demand for scalable gmp production, expansion of gene and immunotherapy pipelines, growing focus on process automation, increasing regulatory scrutiny of cell therapy manufacturing. Major trends in the forecast period include increasing demand for gmp-compliant cell therapy consumables, rising adoption of single-use bioprocessing products, growing use of automated cell processing systems, expansion of standardized cell culture solutions, enhanced focus on quality and regulatory compliance.
The rising prevalence of chronic diseases is expected to drive growth in the GMP cell therapy consumables market. Chronic diseases are illnesses that last three months or longer and can worsen over time. The increase in chronic conditions has spurred research and development of innovative cell therapies aimed at addressing these diseases. As cell therapy applications expand across various chronic conditions, the demand for GMP consumables grows to ensure quality and consistency in clinical trials. Strict regulatory requirements and patient demand for advanced therapies further support market growth. For example, in June 2025, the World Health Organization (WHO), a Switzerland-based organization, reported that 1.8 million avoidable deaths occur annually in the European Region due to chronic noncommunicable diseases. Additionally, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based national library of medicine, projected that the global population with chronic diseases will reach 142.66 million by 2050, up from 71.52 million in 2020. Consequently, the growing prevalence of chronic diseases is fueling demand for GMP cell therapy consumables.
Leading companies in the GMP cell therapy consumables market are focusing on the development of GMP-compliant CD34+ hematopoietic stem cells (HSCs) to enhance advanced therapies. These GMP-compliant CD34+ HSCs are a specific type of stem cell that expresses the CD34 marker on their surface and is produced following Good Manufacturing Practice (GMP) standards. For example, in April 2024, OrganaBio, a US-based pharmaceutical firm, introduced HematoPAC-HSC-CB-GMP, a readily available source of GMP-compliant CD34+ HSCs obtained from fresh human cord blood. Leveraging its extensive expertise in cell isolation and GMP manufacturing, OrganaBio is able to yield high quantities of highly viable CD34+ HSCs within 24 hours post-collection. This launch aims to support the advancement of next-generation therapies for blood cancers and genetic disorders.
In March 2023, Sartorius AG, a Germany-based provider of bioprocess solutions, single-use technologies, and laboratory instruments for the biopharmaceutical industry, acquired Polyplus for approximately €2.4 billion (around US$2.6 billion). Through this acquisition, Sartorius aims to strengthen its position as a leading supplier of critical upstream technologies for cell and gene therapies by integrating Polyplus’s transfection reagents and GMP-grade plasmid DNA into its existing portfolio of cell culture media and other essential bioprocess components. This integration enhances Sartorius’s capability to support viral vector manufacturing workflows for advanced therapies. Polyplus, based in France, provides innovative upstream technologies for cell and gene therapies, developing and producing transfection reagents, DNA/RNA delivery reagents, and GMP-grade plasmid DNA, which are key components in the production of viral vectors for cell and gene therapies and other advanced medicinal products.
Major companies operating in the gmp cell therapy consumables market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Sartorius AG, Corning Incorporated, Avantor Inc., Fresenius Kabi AG, Miltenyi Biotec, Bio-Techne Corp, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., BioLife Solutions Inc., PromoCell GmbH, PeproTech Inc., Sino Biological Inc., Wilson Wolf Corporation, Cellexus Ltd., MaxCyte Inc., BioLegend Inc., Repligen Corporation, Terumo Corporation.
North America was the largest region in the GMP cell therapy consumables market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gmp cell therapy consumables market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gmp cell therapy consumables market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the GMP cell therapy consumables market by increasing costs of imported reagents, culture media, bioprocessing plastics, enzymes, and sterile single-use components used in cell manufacturing workflows. Clinical and commercial manufacturing facilities in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces cost pressure on large-scale production expansion. These tariffs are increasing operational costs and affecting supply continuity. However, they are also encouraging local consumable manufacturing, regional supplier diversification, and strengthened domestic bioprocess supply chains.
The gmp cell therapy consumables market research report is one of a series of new reports that provides gmp cell therapy consumables market statistics, including gmp cell therapy consumables industry global market size, regional shares, competitors with a gmp cell therapy consumables market share, detailed gmp cell therapy consumables market segments, market trends and opportunities, and any further data you may need to thrive in the gmp cell therapy consumables industry. This gmp cell therapy consumables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
GMP cell therapy consumables encompass consumable products and items manufactured in accordance with good manufacturing practices (GMP) guidelines for cell-based therapies. These consumables and tools designed for cell culture assist researchers in cultivating new cells in culture media, catering to various applications such as gene therapy, vaccine production, tissue culture, toxicity testing, and drug development.
The primary categories of GMP cell therapy consumables include kits, reagents or molecular biology reagents, growth factors or cytokines and interleukins, and other essential components. A kit is a compilation of items, such as tools or equipment, intended for a specific activity or purpose. In the realm of GMP cell therapy consumables, kits are utilized for tasks such as the isolation, expansion, harvesting, and formulation of cell therapies. These therapies encompass NK cell therapy, stem cell therapy, T-cell therapy, and others, involving processes such as cell collection and characterization or sorting and separation, cell culture and expansion or preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution or handling, process monitoring and control or re-administration or quality assurance, among others. GMP cell therapy consumables find application in clinical, commercial, and research settings.
The GMP cell therapy consumables market consists of sales of cell culture media, media supplements, extracellular matrices, flasks, tubes, dishes or cryovials, serological pipettes, or centrifugation tubes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. GMP Cell Therapy Consumables Market Characteristics
3. GMP Cell Therapy Consumables Market Supply Chain Analysis
4. Global GMP Cell Therapy Consumables Market Trends and Strategies
5. GMP Cell Therapy Consumables Market Analysis of End Use Industries
7. Global GMP Cell Therapy Consumables Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global GMP Cell Therapy Consumables Total Addressable Market (TAM) Analysis for the Market
9. GMP Cell Therapy Consumables Market Segmentation
10. GMP Cell Therapy Consumables Market Regional and Country Analysis
11. Asia-Pacific GMP Cell Therapy Consumables Market
12. China GMP Cell Therapy Consumables Market
13. India GMP Cell Therapy Consumables Market
14. Japan GMP Cell Therapy Consumables Market
15. Australia GMP Cell Therapy Consumables Market
16. Indonesia GMP Cell Therapy Consumables Market
17. South Korea GMP Cell Therapy Consumables Market
18. Taiwan GMP Cell Therapy Consumables Market
19. South East Asia GMP Cell Therapy Consumables Market
20. Western Europe GMP Cell Therapy Consumables Market
21. UK GMP Cell Therapy Consumables Market
22. Germany GMP Cell Therapy Consumables Market
23. France GMP Cell Therapy Consumables Market
24. Italy GMP Cell Therapy Consumables Market
25. Spain GMP Cell Therapy Consumables Market
26. Eastern Europe GMP Cell Therapy Consumables Market
27. Russia GMP Cell Therapy Consumables Market
28. North America GMP Cell Therapy Consumables Market
29. USA GMP Cell Therapy Consumables Market
30. Canada GMP Cell Therapy Consumables Market
31. South America GMP Cell Therapy Consumables Market
32. Brazil GMP Cell Therapy Consumables Market
33. Middle East GMP Cell Therapy Consumables Market
34. Africa GMP Cell Therapy Consumables Market
36. GMP Cell Therapy Consumables Market Competitive Landscape and Company Profiles
37. GMP Cell Therapy Consumables Market Other Major and Innovative Companies
40. GMP Cell Therapy Consumables Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
GMP Cell Therapy Consumables Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses gmp cell therapy consumables market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gmp cell therapy consumables? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gmp cell therapy consumables market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Kits; Reagents Or Molecular Biology Reagents; Growth Factors Or Cytokines And Interleukins; Other Products2) By Cell Therapy: NK Cell Therapy; Stem Cell Therapy; T-Cell Therapy
3) By Process: Cell Collection And Characterization Or Sorting And Separation; Cell Culture And Expansion Or Preparation; Cryopreservation; Cell Processing And Formulation; Cell Isolation And Activation
4) By End-Use: Clinical; Commercial
Subsegments:
1) By Kits: Cell Culture Kits; Cell Isolation Kits; Transfection Kits2) By Reagents Or Molecular Biology Reagents: Buffers And Solutions; Enzymes; Staining Reagents
3) By Growth Factors Or Cytokines And Interleukins: Hematopoietic Growth Factors; Immunomodulatory Cytokines
4) By Other Products: Cell Culture Vessels; Media And Supplements
Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Lonza Group AG; Sartorius AG; Corning Incorporated; Avantor Inc.; Fresenius Kabi AG; Miltenyi Biotec; Bio-Techne Corp; STEMCELL Technologies Inc.; FUJIFILM Irvine Scientific Inc.; BioLife Solutions Inc.; PromoCell GmbH; PeproTech Inc.; Sino Biological Inc.; Wilson Wolf Corporation; Cellexus Ltd.; MaxCyte Inc.; BioLegend Inc.; Repligen Corporation; Terumo Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this GMP Cell Therapy Consumables market report include:- Thermo Fisher Scientific Inc.
- Merck KGaA
- Lonza Group AG
- Sartorius AG
- Corning Incorporated
- Avantor Inc.
- Fresenius Kabi AG
- Miltenyi Biotec
- Bio-Techne Corp
- STEMCELL Technologies Inc.
- FUJIFILM Irvine Scientific Inc.
- BioLife Solutions Inc.
- PromoCell GmbH
- PeproTech Inc.
- Sino Biological Inc.
- Wilson Wolf Corporation
- Cellexus Ltd.
- MaxCyte Inc.
- BioLegend Inc.
- Repligen Corporation
- Terumo Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 28.79 Billion |
| Forecasted Market Value ( USD | $ 73.96 Billion |
| Compound Annual Growth Rate | 26.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
